Yarlagadda S. Babu
2020
In 2020, Yarlagadda S. Babu earned a total compensation of $2.3M as Chief Discovery Officer at BioCryst Pharmaceuticals, a 109% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $222,789 |
|---|---|
| Option Awards | $1,582,168 |
| Salary | $445,578 |
| Other | $14,250 |
| Total | $2,264,785 |
Babu received $1.6M in option awards, accounting for 70% of the total pay in 2020.
Babu also received $222.8K in non-equity incentive plan, $445.6K in salary and $14.3K in other compensation.
Rankings
In 2020, Yarlagadda S. Babu's compensation ranked 4,974th out of 13,090 executives tracked by ExecPay. In other words, Babu earned more than 62.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,974 out of 13,090 | 62nd |
Division Manufacturing | 2,027 out of 5,621 | 64th |
Major group Chemicals And Allied Products | 803 out of 2,254 | 64th |
Industry group Drugs | 693 out of 1,954 | 65th |
Industry Biological Products, Except Diagnostic Substances | 165 out of 411 | 60th |
Source: SEC filing on April 25, 2022.
Babu's colleagues
We found four more compensation records of executives who worked with Yarlagadda S. Babu at BioCryst Pharmaceuticals in 2020.